Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " BID" to " twice per day") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
{| class="wikitable" style="text-align:center; width:50%;" | {| class="wikitable" style="text-align:center; width:50%;" | ||
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' | ||
|- | |- | ||
|style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]] | |style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.3|center]] | ||
| − | |<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn] | + | |<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle Cancer Care Alliance<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn] |
|- | |- | ||
|} | |} | ||
| Line 16: | Line 13: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| − | |||
=Guidelines= | =Guidelines= | ||
==EMN== | ==EMN== | ||
Revision as of 04:00, 31 January 2019
| Section editor | |
|---|---|
 |
Andrew J. Cowan, MD Seattle Cancer Care Alliance Seattle, WA |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
RD
| back to top |
RD: Revlimid (Lenalidomide) & Dexamethasone
Regimen
| Study | Evidence |
|---|---|
| Nozza et al. 2017 | Phase II, <20 pts |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per week
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
Monthly cycles, continued until progression or excess toxicity
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed